Download PDF
Int J Angiol 2014; 23(02): 111-120
DOI: 10.1055/s-0033-1358383
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Rapamune Does Not Attenuate High Cholesterol-Induced Atherosclerosis in Rabbits

Ahmed Attia
1   Department of Medicine, Royal University Hospital, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
,
Mohamed Ahmed
1   Department of Medicine, Royal University Hospital, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
,
Siew Hon Ng
1   Department of Medicine, Royal University Hospital, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
,
Kailash Prasad
2   Department of Physiology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
,
Ahmed Shoker
1   Department of Medicine, Royal University Hospital, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
› Author Affiliations
Further Information

Publication History

Publication Date:
10 June 2014 (online)

    Permissions and Reprints

Abstract

Solid-organ transplant recipients are prone to develop atherosclerosis. The objectives of this study were to investigate the effects of Rapamune (Wyeth Canada, Saint-Larent, QC, Canada) on the rabbit model of atherosclerosis. The rabbits were assigned to four groups: group I, regular diet (control); group II, 1% cholesterol diet; group III, control with Rapamune (1 mg/kg/d orally); and group IV, high cholesterol diet with Rapamune. Blood samples for serum lipids (triglycerides [TG], total cholesterol [TC], low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C]), as well as malondialdehyde, and protein carbonyls, the indices of oxidative stress were collected at the end of 2 months on the respective diet regimen. Aortic tissue for atherosclerotic changes were also collected for oxidative stress indices were also collected. Rapamune reduced serum levels of TG, TC, LDL-C, and HDL-C. Rapamune elevated the oxidative stress in rabbits on high cholesterol diet. Rapamune did not attenuate extent of atherosclerosis (group II vs. group IV, 45.00 ± 12.00 vs. 57.28 ± 2.99%); intimal thickness (group II vs. group IV, 32.38 ± 7.14 × 103 vs. 21.90 ± 11.98 × 103 μm2); intimal/medial ratio (group II vs. group IV, 0.50 ± 0.06 vs. 0.35 ± 0.06); and macrophage accumulation (group II vs. group IV, 69.72 ± 5.02 vs. 61.52 ± 8.94%) in the intima of rabbits on high cholesterol diet. The data suggest that (1) Rapamune increased the oxidative stress in rabbits on high cholesterol diet and (2) Rapamune did not attenuate the hypercholesterolemic atherosclerosis in the rabbit model.

Keywords

atherosclerosis - Rapamune - serum lipids - malondialdehyde - protein carbonyls - macrophage accumulation - high cholesterol diet
 

  • References

  • 1 Diaz G, O'Connor M. Cardiovascular and renal complications in patients receiving a solid-organ transplant. Curr Opin Crit Care 2011; 17 (4) 382-389
    CrossrefPubMedGoogle Scholar
  • 2 Findlay JY, Wen D, Mandell MS. Cardiac risk evaluation for abdominal transplantation. Curr Opin Organ Transplant 2010; 15 (3) 363-367
    CrossrefPubMedGoogle Scholar
  • 3 Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995; 76 (3) 412-417
    CrossrefPubMedGoogle Scholar
  • 4 Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996; 98 (10) 2277-2283
    CrossrefPubMedGoogle Scholar
  • 5 Stettler C, Wandel S, Allemann S , et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007; 370 (9591) 937-948
    CrossrefPubMedGoogle Scholar
  • 6 Weichhart T, Säemann MD. Sirolimus and kidney transplantation: unraveling an inflammatory affair. Am J Transplant 2010; 10 (12) 2569-2570
    CrossrefPubMedGoogle Scholar
  • 7 Prasad K. Reduction of serum cholesterol and hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. Circulation 1999; 99 (10) 1355-1362
    CrossrefPubMedGoogle Scholar
  • 8 Le NA, Walter MF. The role of hypertriglyceridemia in atherosclerosis. Curr Atheroscler Rep 2007; 9 (2) 110-115
    CrossrefPubMedGoogle Scholar
  • 9 Sakaguchi T, Yan SF, Yan SD , et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 2003; 111 (7) 959-972
    CrossrefPubMedGoogle Scholar
  • 10 Prasad K, Lee P. Suppression of hypercholesterolemic atherosclerosis by pentoxifylline and its mechanism. Atherosclerosis 2007; 192 (2) 313-322
    CrossrefPubMedGoogle Scholar
  • 11 Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31 (5) 335-340
    CrossrefPubMedGoogle Scholar
  • 12 Burke SE, Lubbers NL, Chen YW , et al. Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin. J Cardiovasc Pharmacol 1999; 33 (6) 829-835
    CrossrefPubMedGoogle Scholar
  • 13 Gallo RA, Padurean A, Jayaraman T , et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 1999; 99 (16) 2164-2170
    CrossrefPubMedGoogle Scholar
  • 14 Zhang Q, Lu L, Pu L , et al. Neointimal hyperplasia persists at six months after sirolimus-eluting stent implantation in diabetic porcine. Cardiovasc Diabetol 2007; 6: 16-22
    CrossrefPubMedGoogle Scholar
  • 15 Prasad K, Gupta JB, Kalra J, Lee P, Mantha SV, Bharadwaj B. Oxidative stress as a mechanism of cardiac failure in chronic volume overload in canine model. J Mol Cell Cardiol 1996; 28 (2) 375-385
    CrossrefPubMedGoogle Scholar
  • 16 Kapoor R, Prasad K. Role of oxyradicals in cardiovascular depression and cellular injury in hemorrhagic shock and reinfusion: effect of SOD and catalase. Circ Shock 1994; 43 (2) 79-94
    PubMedGoogle Scholar
  • 17 Prasad K, Kalra J. Oxygen free radicals and hypercholesterolemic atherosclerosis: effect of vitamin E. Am Heart J 1993; 125 (4) 958-973
    CrossrefPubMedGoogle Scholar
  • 18 Gadioli ALN, Nogueira BV, Arruda RM , et al. Oral rapamycin attenuates atherosclerosis without affecting the arterial responsiveness of resistance vessels in apolipoprotein E-deficient mice. Braz J Med Biol Res 2009; 42 (12) 1191-1195
    CrossrefPubMedGoogle Scholar
  • 19 Elloso MM, Azrolan N, Sehgal SN , et al. Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice. Am J Transplant 2003; 3 (5) 562-569
    CrossrefPubMedGoogle Scholar
  • 20 Pakala R, Stabile E, Jang GJ, Clavijo L, Waksman R. Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis. J Cardiovasc Pharmacol 2005; 46 (4) 481-486
    CrossrefPubMedGoogle Scholar
  • 21 Castro C, Campistol JM, Sancho D, Sánchez-Madrid F, Casals E, Andrés V. Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1-independent pathway. Atherosclerosis 2004; 172 (1) 31-38
    CrossrefPubMedGoogle Scholar
  • 22 Morales JM. Cardiovascular size profile in patients treated with sirolimus after renal transplantation. Kidney Int Suppl 2005; 93: S69-S73
    PubMedGoogle Scholar
  • 23 Blum CB. Effects of sirolimus on lipids in renal allograft recipients: an analysis using the Framingham risk model. Am J Transplant 2002; 2 (6) 551-559
    CrossrefPubMedGoogle Scholar
  • 24 Brattström C, Wilczek H, Tydén G, Böttiger Y, Säwe J, Groth CG. Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation 1998; 65 (9) 1272-1274
    CrossrefPubMedGoogle Scholar
  • 25 Reis F, Parada B, Teixeira de Lemos E , et al. Hypertension induced by immunosuppressive drugs: a comparative analysis between sirolimus and cyclosporine. Transplant Proc 2009; 41 (3) 868-873
    CrossrefPubMedGoogle Scholar
  • 26 Prasad K , et al. Oxygen free radicals as a mechanism of hypercholesterolemic atherosclerosis: effects of probucol. Int J Angiol 1994; 3: 100-112
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Verheye S, Martinet W, Kockx MM , et al. Selective clearance of macrophages in atherosclerotic plaques by autophagy. J Am Coll Cardiol 2007; 49 (6) 706-715
    CrossrefPubMedGoogle Scholar
  • 28 Morrisett JD, Abdel-Fattah G, Hoogeveen R , et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 2002; 43 (8) 1170-1180
    PubMedGoogle Scholar
  • 29 Groth CG, Bäckman L, Morales JM , et al; Sirolimus European Renal Transplant Study Group. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999; 67 (7) 1036-1042
    CrossrefPubMedGoogle Scholar
  • 30 Prasad K. Regression of hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. Atherosclerosis 2008; 197 (1) 34-42
    CrossrefPubMedGoogle Scholar
  • 31 Geurian K, Pinson JB, Weart CW. The triglyceride connection in atherosclerosis. Ann Pharmacother 1992; 26 (9) 1109-1117
    PubMedGoogle Scholar
  • 32 Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol 2002; 1: 1-10
    CrossrefPubMedGoogle Scholar
  • 33 Ma KL, Ruan XZ, Powis SH, Moorhead JF, Varghese Z. Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2007; 292 (6) H2721-H2728
    CrossrefPubMedGoogle Scholar
  • 34 Naoum JJ, Woodside KJ, Zhang S, Rychahou PG, Hunter GC. Effects of rapamycin on the arterial inflammatory response in atherosclerotic plaques in Apo-E knockout mice. Transplant Proc 2005; 37 (4) 1880-1884
    CrossrefPubMedGoogle Scholar
  • 35 Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7: 145-173
    CrossrefPubMedGoogle Scholar
  • 36 Gupta S, Pablo AM, Jiang Xc, Wang N, Tall AR, Schindler C. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest 1997; 99 (11) 2752-2761
    CrossrefPubMedGoogle Scholar
  • 37 Assoian RK, Sporn MB. Type beta transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells. J Cell Biol 1986; 102 (4) 1217-1223
    CrossrefPubMedGoogle Scholar